POLYMORPHIC VARIANTS IN THE CYP3A4 GENE, CYSTIC FIBROSIS, AND THE RISK OF ADVERSE REACTIONS TO ANTIBACTERIAL THERAPY IN CHILDREN

Download full text PDF
Issue: 
10
Year: 
2017

O. Novoselova (1, 2); Professor E. Kondratyeva (1), MD; N. Petrova (1), Doctor of Biological Sciences; R. Bikanov (1), Professor R. Zinchenko (1, 3), MD 1-Research Center of Medical Genetics, Moscow 2-N.F. Filatov City Children's Hospital Thirteenth, Moscow 3-N.I. Pirogov Russian National Research Medical University, Moscow

Chronic pulmonary infection is a consequence of impaired mucociliary clearance in cystic fibrosis (CF). Patients with CF receive long-term cycles of high-dose antibacterial therapy (ABT). A study of the causes of antibiotic resistance and adverse reactions (ARs) is promising in these patients. The impact of polymorphic variants in the CYP3A4 gene on the risk of ARs during ABT and on the predisposition to gram-negative infection was investigated in children with CF.

Keywords: 
pulmonology
cystic fibrosis
first-phase biotransformation system genes
cytochromes P450
adverse reactions
antibiotic therapy



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Hersh A., Shapiro D., Pavia A. et al. Antibiotic prescribing in ambulatory pediatrics in the United States // Pediatrics. – 2011; 128: 1053–61.
  2. Versporten A., Sharland M., Bielicki J. et al. ARPEC Project Group Members. The Antibiotic Resistance and Prescribing in European Children Project: a neonatal and pediatric antimicrobial Web-based point prevalence survey in 73 hospitals worldwide // Pediatr. Infect. Dis. J. – 2013; 32: e242–53.
  3. Anderson B., Holford N. Tips and traps analyzing pediatric PK data // Paediatr. Anaesth. – 2011; 21: 222–37.
  4. Kapranov N.I., Kashirskaja N.Ju., Asherova I.K. i dr. Istoricheskie i sovremennye aspekty mukovistsidoza v Rossii // Pediatricheskaja farmakologija. – 2013; 10 (6): 53–60.
  5. Gibson R., Burns J., Ramsey B. Pathophysiology and management of pulmonary infections in cystic fibrosis // Am. J. Respir. Crit. Care Med. – 2003; 168 (8): 918–51.
  6. Mishra A., Greaves R., Massie J. The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era // Clin. Biochem. Rev. – 2005; 26 (4): 135–53.
  7. Koch C., Cuppens H., Rainisio M. et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations // Pediatr. Pulmonol. – 2001; 31 (1): 1–12.
  8. Mukovistsidoz. Pod red. N.I. Kapranova, N.Ju. Kashirskoj / M.: MEDPRAKTIKA-M, 2014; 672 s
  9. Tramper-Stranders G., van der Ent C., Molin S. et al. Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates // Clin. Microbiol. Infect. – 2012; 18 (6): 567–74.
  10. Asherova I.K., Kapranov N.I. Mukovistsidoz – mediko-sotsial'naja problema // M.: OOO «Tipografija Jaroslavskij pechatnyj dvor», 2013; 236 s.
  11. Natsional'nyj konsensus «Mukovistsidoz: opredelenie, diagnosticheskie kriterii, terapija». Pod red. E.I. Kondrat'evoj, N.Ju. Kashirskoj, N.I. Kapranova / M: OOO «Kompanija BORGES», 2016; 205 s.
  12. Shaginjan I.A., Kapranov N.I., Chernuha M.Ju. i dr. Mikrobnyj pejzazh nizhnih dyhatel'nyh putej u razlichnyh vozrastnyh grupp detej, bol'nyh mukovistsidozom // Zhurn. mikrobiol., epidemiol. i infekts. boleznej. – 2009; 5: 15–20.
  13. Guss A., Roeselers G., Newton I. et al. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis // ISMEJ. – 2011; 5 (1): 20–9.
  14. Krasovskij S.A., Chernjak A.V., Kondrat'eva E.I. i dr. Mukovistsidoz v Rossii: sozdanie natsional'nogo registra // Pediatrija. Zhurn. im. G.N. Speranskogo. – 2014; 93 (4): 44–55.
  15. Sgro C., Clinard F., Ouazir K. et al. Incidence of drug-induced hepatic injuries: A French populationbased study // Hepatology. – 2002; 36: 451–5. [PubMed: 12143055]
  16. Ostapowicz G., Fontana R., Schiodt F. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States // Ann. Intern. Med. – 2002; 137: 947–54. [PubMed: 12484709]
  17. Wedi B. Definitions and mechanisms of drug hypersensitivity // Expert Rev. Clin. Pharmacol. – 2010; 3 (4): 539–51. [PubMed: 22111682]
  18. Johansson S., Hourihane J., Bousquet J. et al. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force // Allergy. – 2001; 56 (9): 813–24. [PubMed: 11551246]
  19. Posadas S., Pichler W. Delayed drug hypersensitivity reactions – new concepts // Clin. Exp. Allergy. – 2007; 37 (7): 989–99. [PubMed: 17581192]
  20. Sim S., Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects // Human Genomics. – 2010; 4 (4): 278–81. DOI:10.1186/1479-7364-4-4-278.
  21. http://www.cypalleles.ki.se/
  22. Sim S., Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects // Human Genomics. – 2010; 4 (4): 278–81. DOI:10.1186/1479-7364-4-4-278.
  23. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research // Toxicol. Appl. Pharmacol. – 2005; 207 (2 Suppl.): 52–6.
  24. Guengerich F. Cytochrome p450 and chemical toxicology // Chem. Res. Toxicol. – 2008; 21 (1): 70–83.
  25. The Pharmacogenomics Knowledge Base. CPIC Gene-Drug Pairs. http://www.pharmgkb.org/page/cpicGeneDrugPairs. Accessed April 2, 2014.
  26. Kisor D., Kane M., Talbot J. et al. Introduction to Personalized Medicine. In: Pharmacogenetics, Kinetics, and Dynamics for Personalized Medicine / Burlington, Massachusetts: Jones & Bartlett Learning; 2014; pp. 3–37.
  27. Lown K., Bailey D., Fontana R. et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression // J. Clin. Invest. – 1997; 99: 2545–53. [PubMed: 9153299]
  28. Preissner S., Hoffmann M., Preissner R. et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy // PLOS One. – 2013; 8 (Issue 12): e82562.
  29. Registr bol'nyh mukovistsidozom v Rossijskoj Federatsii, 2013 god. Pod red. N.Ju. Kashirskoj / M.: MEDPRAKTIKA-M, 2015, 64 s.
  30. Registr bol'nyh mukovistsidozom v Rossijskoj Federatsii, 2014 god / M.: MEDPRAKTIKA-M, 2015; 64 s.
  31. Recommendations for the classification of diseases as CFTR-related disorders // J. Cyst. Fibros. – 2011; 10 (Suppl. 2): 86–102.
  32. Preissner S., Hoffmann M., Preissner R. et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy // PLOS One. – 2013; 8 (Issue 12): e82562.
  33. Gaikovitch E., Cascorbi I., Mrozikiewicz P. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population // Eur. J. Clin. Pharmacol. – 2003; 59 (4): 303–12.
  34. Churnosov M.I., Poljakova I.S., Pahomov S.P. i dr. Molekuljarnye i geneticheskie mehanizmy biotransformatsii ksenobiotikov // Nauchnye vedomosti BelGU. Serija: Meditsina. Farmatsija. – 2011; 16 (111): 223–8.
  35. Plummer A., Wildman M., Gleeson T. Duration of intravenous antibiotic therapy in people with cystic fibrosis // Cochrane Database Syst. Rev. – 2016; 9: CD006682. [Epub ahead of print] Review. PubMed PMID: 27582394.
  36. Westervelt P., Cho K., Bright D. et al. Drug–Gene Interactions: Inherent Variability In Drug Maintenance Dose Requirements // Pharmacy and Therapeutics. – 2014; 39 (9): 630–7.
  37. Preissner S., Hoffmann M., Preissner R. et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy // PLOS One. – 2013; 8 (Issue 12): e82562.
  38. Shabalova L.I., Polikarpova S.V., Pivkina N.V. i dr. Opyt primenenija kolistimetata natrija (kolistina) pri sinegnojnoj infektsii u detej c mukovistsidozom // Pediatrija. Zhurn. im. G.N. Speranskogo. – 2016; 95 (6): 85–8.